HOME> product


Bioactivity bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs[1].
Name bPiDI
CAS 525596-64-9
Formula C22H34I2N2
Molar Mass 580.33
Appearance 固体
Transport Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Reference [1]. Thomas E Wooters, et al. bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol. 2011, 163,2.

About Contact

© 2008-2024 PeptideDB SYSTEM All Rights Reserved